| 2026-08-20 | Press release | Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 |
| 2026-08-19 | Deck | Q2:2026 Business Update and Financial Results |
| 2026-08-06 | Deck | Angelman Syndrome Program Update |
| 2026-07-29 | Press release | Ionis announces Dr. Frank Bennett, chief scientific officer, to retire |
| 2026-07-29 | Press release | Ionis reports second quarter 2026 financial results and highlights progress on key programs |
| 2026-07-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-29 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-29 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-15 | Press release | Ionis to hold second quarter 2026 financial results webcast |
| 2026-07-14 | Press release | Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduc |
| 2026-07-13 | Press release | Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome |
| 2026-07-10 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-09 | Press release | Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy – Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy |
| 2026-07-09 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-06 | Press release | Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome - Topline data from REVEAL anticipated in 2H 2027 |
| 2026-06-25 | Deck | Investor presentation · Jun 2026 |
| 2026-06-25 | Press release | Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S |
| 2026-06-24 | Press release | TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) |
| 2026-06-24 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-15 | Deck | PREVENTION OF ACUTE PANCREATITIS WITH APOC3 INHIBITION IN SEVERE HYPERTRIGLYCERIDEMIA ACROSS TRIGLYCERIDE LEVELS AND PRIOR PANCREATITIS |
| 2026-06-12 | Document | APOLIPOPROTEIN C-III (APOC3) INHIBITION FOR SEVERE HYPERTRIGLYCERIDEMIA IN PATIENTS WITH VERSUS WITHOUT BASELINE FIBRATE USE A PRE-SPECIFIED SECONDARY ANALYSIS OF THE CORE-TIMI 72A AND CORE2-TIMI 72B TRIALS |
| 2026-06-12 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-11 | Press release | Relationship Between PROMIS® 29+2 and Home-Reported Outcomes (HROs) in a Population with Severe Hypertriglyceridemia (sHTG) |
| 2026-06-08 | Press release | Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors |
| 2026-06-08 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-04 | Press release | Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses |
| 2026-05-30 | Press release | Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen |
| 2026-05-28 | Press release | Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B |
| 2026-05-28 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-21 | Press release | Enhanced splicing modulation by NMA-modified antisense oligonucleotides |
| 2026-05-14 | Press release | Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease |
| 2026-05-06 | Deck | Eplontersen in hereditary ATTR-polyneuropathy: Week 66 final analysis of the phase 3 NEURO-TTRansform study |
| 2026-05-01 | Press release | Ionis to present at upcoming investor conferences |
| 2026-04-29 | Press release | Ionis reports first quarter 2026 financial results and highlights progress on key programs |
| 2026-04-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-29 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-28 | Press release | Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-04-21 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-15 | Press release | Ionis to hold first quarter 2026 financial results webcast |